Plasma sodium and mortality risk in patients with myocardial infarction and a low LVEF

European Journal of Clinical Investigation

Volumn 41, Issue 11, 2011, Pages 1237-1244

  Schou, Morten ^a,b   Valeur, Nana ^c   Torp Pedersen, Christian ^c   Gustafsson, Finn ^a   Køber, Lars ^a  

^a Rigshospitalet   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hyponatremia; Left ventricular systolic dysfunction; Mortality risk; Myocardial infarction; Plasma sodium

Indexed keywords

PLACEBO; TRANDOLAPRIL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPONATREMIA; INDOLES; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80053928108     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02532.x     Document Type: Article

References (32)

1. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164-8.
2. Chung HM, Kluge R, Schrier RW, Anderson RJ. Postoperative hyponatremia. A prospective study. Arch Intern Med 1986;146:333-6.
3. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
4. Szatalowicz VL, Arnold PE, Chaimovitz C. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6.
5. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-67.
6. Kumar S, Berl T. Sodium. Lancet 1998;352:220-8.
7. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 1993;126:1068-76.
8. Goldberg A, Hammerman H, Petcherski S, Nassar M, Zdorovyak A, Yalonetsky S et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 2006;166:781-6.
9. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.
10. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431-9.
11. Kober L, Torp-Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol 1995;76:1-5.
12. Kober L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H. Echocardiographic methods for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril CardiacEvaluation. Eur Heart J 1994;15:1616-20.
13. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) StudyGroup. N Engl J Med 1995;333:1670-6.
14. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M et al. Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction. Am J Med 2004;117:242-8.
16. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43.
17. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
18. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-10.
19. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007;167:1998-2005.
20. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
21. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 2008;29:2489-96.
22. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-42.
23. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
24. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
25. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
27. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
28. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-85.
29. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
30. Meta-Analysis Research Group in Echocardiography (MeRGE) AMI Collaborators, Møller JE, Whalley GA, Dini FL, Doughty RN, Gamble GD et al. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation 2008;117:2591-8.
31. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003;107:2207-12.
32. Smilde TD, van Veldhuisen VJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;10:114.